These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

811 related items for PubMed ID: 26991643

  • 1. Efficacy of Adding Dutasteride to α-Blocker Therapy Treated Benign Prostatic Hyperplasia Patients with Small Volume Prostate (<30 mL).
    Hashimoto M, Shimizu N, Sugimoto K, Hongoh S, Minami T, Nozawa M, Yoshimura K, Hirayama A, Tahara H, Uemura H.
    Low Urin Tract Symptoms; 2017 Sep; 9(3):157-160. PubMed ID: 26991643
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker : its effect on overactive bladder].
    Wada N, Hashidume K, Tamaki G, Kita M, Iwata T, Matsumoto S, Kakizaki H.
    Hinyokika Kiyo; 2012 Sep; 58(9):475-80. PubMed ID: 23070385
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: a prospective, pilot study.
    Shindo T, Hashimoto K, Shimizu T, Itoh N, Masumori N.
    Korean J Urol; 2015 Apr; 56(4):305-9. PubMed ID: 25874044
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Additional administration of dutasteride in patients with benign prostatic hyperplasia who did not respond sufficiently to α1-adrenoceptor antagonist : investigation of clinical factors affecting the therapeutic effect of dutasteride].
    Masuda M, Murai T, Osada Y, Kawai M, Kasuga J, Yokomizo Y, Kuroda S, Nakamura M, Noguchi G.
    Hinyokika Kiyo; 2014 Feb; 60(2):61-7. PubMed ID: 24755815
    [Abstract] [Full Text] [Related]

  • 8. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP.
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The cutoff value of transitional zone index predicting the efficacy of dutasteride on subjective symptoms in patients with benign prostate hyperplasia.
    Kurokawa S, Kamei J, Sakata K, Sugihara T, Fujisaki A, Ando S, Takayama T, Fujimura T.
    Low Urin Tract Symptoms; 2022 Jul; 14(4):261-266. PubMed ID: 35170856
    [Abstract] [Full Text] [Related]

  • 11. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia.
    Joo KJ, Sung WS, Park SH, Yang WJ, Kim TH.
    J Int Med Res; 2012 Jul; 40(3):899-908. PubMed ID: 22906262
    [Abstract] [Full Text] [Related]

  • 12. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R, Miyazato M, Nishii H, Sumino Y, Takayama K, Onzuka M, Oshiro T, Saito S, Fujimoto N, Mimata H, Eto M.
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [Abstract] [Full Text] [Related]

  • 13. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [Abstract] [Full Text] [Related]

  • 14. Dutasteride add-on treatment to tadalafil for patients with benign prostatic enlargement is similarly effective as dutasteride add-on treatment to alpha blocker: a propensity-score matching analysis.
    Wada N, Abe N, Miyauchi K, Ishikawa M, Makino S, Kakizaki H.
    Int Urol Nephrol; 2022 Jun; 54(6):1193-1198. PubMed ID: 35362820
    [Abstract] [Full Text] [Related]

  • 15. A prospective, randomized, open-label, parallel trial comparing the efficacy of α-blocker or 5α-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Lee KS, Yoo JW, Kim DH, Jeon S, Yang J, Chung BH, Koo KC.
    Prostate; 2024 Mar; 84(4):403-413. PubMed ID: 38149792
    [Abstract] [Full Text] [Related]

  • 16. Modeling study of the effect of placebo and medical therapy on storage and voiding symptoms, nocturia, and quality of life in men with prostate enlargement at risk for progression.
    Gravas S, Manuel-Palacios J, Chavan C, Roehrborn CG, Oelke M, Averbeck MA, Biswas A, García LM, Mohamed K, Cortes V.
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):469-477. PubMed ID: 37794168
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A comparison of the efficacy of dutasteride on reducing lower urinary tract symptoms among patients with small versus large benign prostatic hyperplasia.
    Shigehara K, Kato Y, Kawaguchi S, Izumi K, Kadono Y, Mizokami A.
    Curr Urol; 2024 Sep; 18(3):199-202. PubMed ID: 39219636
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement.
    Wada N, Matsumoto S, Kita M, Hashizume K, Kakizaki H.
    Low Urin Tract Symptoms; 2015 Jan; 7(1):37-41. PubMed ID: 26663650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.